MARKET

RGNX

RGNX

Regenxbio
NASDAQ
14.59
+1.08
+7.99%
After Hours: 14.61 +0.02 +0.14% 18:37 12/19 EST
OPEN
13.79
PREV CLOSE
13.51
HIGH
15.20
LOW
13.51
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
15.20
52 WEEK LOW
5.04
MARKET CAP
738.59M
P/E (TTM)
-4.2136
1D
5D
1M
3M
1Y
5Y
1D
Regenxbio price target raised to $45 from $40 at Stifel
TipRanks · 20h ago
REGENXBIO INC <RGNX.O>: STIFEL RAISES TARGET PRICE TO $45 FROM $40
Reuters · 20h ago
Regenxbio Inc. to Present at J.P. Morgan Healthcare Conference
Reuters · 1d ago
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR Newswire · 1d ago
REGENXBIO Price Target Raised to $20.00/Share From $16.00 by Leerink Partners
Dow Jones · 4d ago
REGENXBIO Is Maintained at Outperform by Leerink Partners
Dow Jones · 4d ago
Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $20
Benzinga · 4d ago
Regenxbio price target raised to $20 from $16 at Leerink
TipRanks · 4d ago
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.